Axsome Therapeutics Analysts Increase Their Forecasts After Q2 Earnings
1. Axsome reported Q2 losses of $0.47 versus $1.07 expected loss. 2. Quarterly sales reached $150.04 million, beating estimates of $140.33 million. 3. Recent approval of SYMBRAVO and ongoing sales of AUVELITY are promising. 4. Analysts maintain positive ratings and raise price targets for AXSM. 5. AXSM shares decreased by 3.4% despite the strong earnings report.